govt.chinadaily.com.cn

Resources

Technical guideline for the inoculation of COVID-19 vaccines

Updated: Apr 1, 2021 By Zou Shuo and Ma Chi chinadaily.com.cn Print
Share - WeChat
A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd in Beijing, March 16, 2020. [Photo/Xinhua]

So far, China has approved four COVID-19 vaccines for conditional marketing and one for emergency use. Phase III clinical trials of three inactivated vaccines and one adenovirus vaccine approved for conditional marketing show their efficacy rates meet the requirements of the National Medical Products Administration and the World Health Organization. Phase II trials of the recombinant protein subunit vaccine (CHO cell) approved for emergency use show the vaccine is safe and can induce a strong immune response.

The National Health Commission has published a guideline on the use of COVID-19 vaccines. Here is some key information from the guideline.

1. Types of vaccines:

(1) Inactivated vaccine

The three inactivated vaccines are respectively made by Beijing Biological Products Institute Co Ltd and Wuhan Institute of Biological Products Co Ltd, two affiliates of China National Pharmaceutical Group Co Ltd (SinoPharm), and Sinovac Biotech Ltd.

(2) Adenovirus vector vaccine

The adenovirus vector vaccine is made by CanSino Biologics Inc.

(3) Recombinant protein subunit vaccine

This vaccine is produced by the Anhui Zhifei Longcom Biopharmaceutical Co Ltd.

1 2 3 4 >

Copyright©2021 China Daily. All rights reserved.

京ICP备13028878号-6

京公网安京公网安备 11010502032503号